Myelodysplastic syndrome transformation represents a critical turning point in a group of bone marrow disorders where blood cells don’t develop properly. Understanding the treatment options during this challenging phase—from managing symptoms to exploring cutting-edge therapies in clinical trials—can help patients and their families navigate this complex medical journey with greater confidence.

When the Bone Marrow Takes a Dangerous Turn

Myelodysplastic syndromes, often shortened to MDS, are conditions that affect how bone marrow produces blood cells. In healthy individuals, bone marrow continuously creates new red blood cells to carry oxygen, white blood cells to fight infection, and platelets to help blood clot. In MDS, this process goes wrong at the earliest stages, and the cells that are produced either don’t mature properly or die before they can do their job. For some people living with MDS, the condition remains relatively stable for years. But for others, something more concerning happens—the disease transforms into acute myeloid leukemia, a type of blood cancer where immature cells called blasts rapidly take over the bone marrow.^[1]

This transformation doesn’t happen to everyone with MDS. About one-third of people with myelodysplastic syndromes will eventually experience this shift toward acute leukemia. When MDS begins changing in this way, the percentage of immature blast cells in the bone marrow increases. Medical professionals typically reclassify MDS as acute myeloid leukemia when blast cells reach or exceed 20 percent of the bone marrow cells. This boundary matters because the treatment approaches and outlook change significantly once transformation occurs.^[1]

The transformation process itself varies tremendously from person to person. Some individuals progress quickly, within months of their initial MDS diagnosis. Others may live with stable disease for many years before any transformation begins. The time it takes for transformation to occur, along with other factors like the specific genetic abnormalities present and the number of blast cells at diagnosis, all influence what happens next and how doctors plan treatment.^[4]

Treatment Goals When MDS Transforms

When myelodysplastic syndrome transforms toward acute leukemia, treatment goals shift in important ways. Unlike lower-risk MDS where the focus might be on managing symptoms and improving quality of life through supportive care, transformation creates a more urgent situation. The primary goals during and after transformation include slowing the progression of disease, managing serious complications that arise from having too few healthy blood cells, and in some cases, attempting to cure the disease entirely through intensive treatment.^[8]

Treatment decisions depend heavily on several individual factors. A person’s age matters significantly—younger patients may tolerate more aggressive therapies better than older individuals. The presence of other health conditions, called comorbidities, also influences which treatments are safe and appropriate. A person’s overall physical condition, often measured using something called the Eastern Cooperative Oncology Group performance status (a scale that rates how well someone can carry out daily activities), helps doctors determine treatment intensity. Personal goals and preferences play a role too—what matters most to the individual patient should guide decisions about pursuing aggressive therapy versus focusing on quality of life.^[4]

The transformation to acute leukemia brings additional challenges because this form of leukemia that develops from MDS tends to respond less well to standard chemotherapy drugs compared to acute myeloid leukemia that develops on its own without prior MDS. This reality makes treatment planning more complex and underscores why research into new therapies remains so critical.^[1]

Standard Treatment Approaches

The standard treatment landscape for myelodysplastic syndrome transformation centers on several established approaches that medical societies and organizations have studied and recommended. These treatments aim to control the disease, reduce symptoms, and prevent life-threatening complications.

Supportive Care Measures

Supportive care forms the foundation of treatment for many people dealing with MDS transformation. This approach focuses on replacing what the failing bone marrow cannot produce. Blood transfusions provide immediate relief when red blood cell counts drop dangerously low, helping people feel less fatigued and breathless. When platelet counts fall, platelet transfusions can prevent serious bleeding complications. These transfusions don’t treat the underlying disease, but they address the immediate consequences of bone marrow failure and can significantly improve quality of life.^[13]

Using specially prepared blood products makes a meaningful difference in transfusion safety. Leukocyte-depleted blood products—meaning red blood cells or platelets from which white blood cells have been removed—reduce the risk of fever reactions, prevent the immune system from developing antibodies against transfused cells, and lower the chance of transmitting certain viruses. Healthcare professionals also manage infections aggressively when they occur, since low white blood cell counts leave people vulnerable to bacteria, viruses, and fungi that healthy immune systems would normally control easily.^[13]

Hypomethylating Agents

For patients with higher-risk MDS, including those showing signs of transformation, drugs called hypomethylating agents have become a standard treatment option. The two main medications in this category are azacitidine and decitabine. These drugs work by affecting how genes in cancer cells are turned on or off. Specifically, they block certain chemical modifications on DNA that would normally silence genes. By removing these modifications, hypomethylating agents can sometimes restore more normal blood cell development.^[8]

Azacitidine and decitabine are currently the only approved treatment options beyond supportive care for people with higher-risk myelodysplastic syndromes who are not candidates for bone marrow transplantation. These medications are particularly valuable for older patients who might not tolerate intensive chemotherapy well. Treatment typically involves receiving the medication through an injection under the skin or into a vein, following specific schedules that repeat in cycles. Azacitidine, for example, is often given for seven days in a row, followed by a rest period, with this cycle repeating every 28 days.^[13]

While hypomethylating agents can help some people, they don’t work for everyone. When they do work, they may slow disease progression, reduce the need for transfusions, and improve blood counts. However, many patients eventually stop responding to these medications, and once that happens, treatment options become more limited. The median survival time after hypomethylating agent failure remains disappointingly short, highlighting the urgent need for better therapies.^[8]

Immunomodulatory Drugs

Lenalidomide represents another important treatment option, though it works best for a specific subset of patients. This immunomodulatory drug—meaning a medication that affects immune system function—is approved specifically for people with lower-risk MDS who have a particular genetic abnormality called deletion 5q (or del(5q)). In these individuals, a piece of chromosome 5 is missing from their cells. Lenalidomide can be remarkably effective for this group, often reducing or eliminating the need for red blood cell transfusions.^[13]

For patients without the del(5q) abnormality, lenalidomide is less consistently helpful, though some people still respond. The medication comes as a pill taken by mouth, typically once daily for part of each treatment cycle. Common side effects include low blood counts (which might seem counterintuitive for a drug meant to treat low blood counts, but the initial effect can sometimes make counts worse before they improve), increased risk of blood clots, diarrhea, itching, and rash.^[13]

Intensive Chemotherapy

When MDS transforms into acute leukemia, some patients—particularly younger individuals in good overall health—may receive intensive chemotherapy similar to what’s used for acute myeloid leukemia that develops without prior MDS. The most common regimen combines cytarabine (also called ara-C) with an anthracycline drug like daunorubicin or idarubicin. This combination, sometimes called “7+3” because of the typical dosing schedule, aims to rapidly kill leukemia cells in the bone marrow.^[5]

Unfortunately, acute leukemia arising from MDS responds to intensive chemotherapy less often than acute leukemia that develops on its own. Response rates typically range from 30 to 40 percent, meaning that fewer than half of patients achieve complete disease remission with this approach. The treatment itself carries significant risks, including severe drops in blood counts that leave people vulnerable to life-threatening infections and bleeding. Patients receiving intensive chemotherapy typically require hospitalization for several weeks while their blood counts recover.^[5]

Hematopoietic Stem Cell Transplantation

Currently, allogeneic hematopoietic stem cell transplantation—commonly called bone marrow transplant—remains the only treatment that can potentially cure myelodysplastic syndromes and prevent transformation. This procedure involves replacing a person’s diseased bone marrow with healthy stem cells from a donor. Before the transplant, patients receive high-dose chemotherapy or radiation to eliminate their existing bone marrow. Then, stem cells from a matched donor are infused into the bloodstream, where they travel to the bone marrow and, if successful, begin producing healthy blood cells.^[8]

Despite being potentially curative, stem cell transplantation comes with substantial risks and limitations. The procedure works best in younger patients without significant other health problems. Finding a suitable donor—ideally a sibling or unrelated person whose tissue type closely matches the patient’s—can be challenging. The transplant process itself carries risks of serious complications, including infections, organ damage, and graft-versus-host disease, where the donor immune cells attack the recipient’s tissues. Even with successful transplantation, disease relapse remains a significant concern, particularly in patients who had higher-risk disease before transplant.^[8]

Because of these factors, only a minority of MDS patients ultimately undergo stem cell transplantation. The majority—particularly older individuals or those with other health conditions—are not medically suitable candidates for this intensive procedure. For these patients, other treatment approaches must be considered.^[8]

Emerging Therapies in Clinical Trials

Given the limitations of current standard treatments, particularly after MDS transforms or after hypomethylating agents stop working, researchers are actively studying many new approaches in clinical trials. These investigational therapies aim to target the disease through different mechanisms, potentially offering options for people who have exhausted standard treatments.

Understanding Clinical Trial Phases

Before discussing specific experimental treatments, it helps to understand how clinical trials work. When researchers develop a new therapy, it goes through several testing phases. Phase I trials focus primarily on safety—determining what dose of a new drug people can tolerate and what side effects occur. These trials usually involve small numbers of patients. Phase II trials expand the group and begin assessing whether the treatment actually works against the disease. Phase III trials are large studies that compare the new treatment directly against the current standard treatment to determine if the experimental therapy offers advantages.^[6]

Targeted Molecular Therapies

Scientists have identified numerous genetic mutations that contribute to MDS development and transformation. This knowledge has spurred development of targeted therapies designed to block specific abnormal proteins or pathways in cancer cells. For example, researchers are studying drugs that inhibit particular enzymes involved in DNA modification or cell signaling.

One area of active investigation involves targeting mutations in genes like TP53, which normally helps prevent cancer but stops working properly when mutated. Patients with TP53 mutations tend to have particularly aggressive disease with poor outcomes after transformation. The presence of TP53 mutations has been identified as an independent factor predicting shorter survival. New drugs that might overcome the effects of TP53 mutations are being tested in early-phase trials.^[4]

Other targeted approaches focus on mutations in genes involved in how cells process genetic information. Many MDS patients have mutations in genes like TET2, SF3B1, or ASXL1. Researchers are developing compounds that specifically target the abnormal proteins produced by these mutated genes. Some of these experimental drugs have shown promise in laboratory studies and early clinical trials, though larger studies are needed to determine their true effectiveness.^[10]

Combination Approaches with Hypomethylating Agents

Since hypomethylating agents like azacitidine and decitabine represent current standard care for higher-risk MDS, many clinical trials are testing whether adding other drugs to these agents improves outcomes. The idea behind combination therapy is that attacking the disease through multiple mechanisms simultaneously might be more effective than using a single drug alone.

Researchers have conducted numerous trials combining hypomethylating agents with other types of medications, including immunotherapy drugs, targeted molecular inhibitors, and other chemotherapy agents. Unfortunately, many of these combination studies have not shown clear benefits compared to using hypomethylating agents alone. Some combinations produced more side effects without improving survival or other important outcomes. This doesn’t mean combination approaches won’t eventually succeed, but it highlights that simply adding more drugs together doesn’t guarantee better results.^[10]

Current combination trials continue to explore new drug pairs, refined dosing schedules, and selection of patients most likely to benefit based on their specific genetic abnormalities. Some ongoing studies are examining whether certain combinations work better for particular MDS subtypes or mutation patterns.

Immunotherapy Approaches

Immunotherapy—treatments that harness the body’s immune system to fight disease—has revolutionized treatment for several cancer types in recent years. Researchers are working to determine whether similar approaches might help people with MDS and transformed disease.

One immunotherapy strategy involves checkpoint inhibitors, drugs that release brakes on immune cells, allowing them to attack cancer cells more effectively. These medications have shown remarkable success against certain solid tumors and some blood cancers. Clinical trials are testing whether checkpoint inhibitors, either alone or combined with hypomethylating agents, can benefit MDS patients. Early results have been mixed, with some patients responding but many not benefiting. Research continues to identify which patients might be most likely to respond.^[10]

Another immunotherapy approach involves engineering a patient’s own immune cells to recognize and attack MDS cells. These modified cells, called CAR-T cells, are created by collecting immune cells from the patient’s blood, genetically modifying them in a laboratory to target specific proteins on MDS cells, and then infusing them back into the patient. CAR-T cell therapy has shown success against certain leukemias and lymphomas and is now being adapted and tested for MDS in early clinical trials.

Novel Classes of Drugs

Beyond targeted therapies and immunotherapies, researchers are investigating entirely new classes of drugs for MDS. Some of these take advantage of unique vulnerabilities in MDS cells.

Luspatercept represents one recently approved agent that works differently from traditional MDS drugs. This medication, approved for lower-risk MDS patients who require red blood cell transfusions and have ring sideroblasts (a specific cell abnormality), helps improve red blood cell production. It works by blocking certain signaling pathways that interfere with normal red blood cell maturation. Clinical trials showed that luspatercept could reduce transfusion needs in appropriate patients. While not specifically focused on transformation, such agents represent the kind of innovative thinking driving new drug development.^[8]

Imetelstat is another novel agent that works through a unique mechanism. This drug inhibits an enzyme called telomerase, which cancer cells use to maintain their ability to divide indefinitely. By blocking telomerase, imetelstat may limit MDS cell growth. Clinical trials have shown that imetelstat can reduce transfusion requirements and, importantly, reduce the burden of mutated cells in some patients—one of the few drugs shown to do so.^[10]

Clinical Trial Access and Eligibility

Clinical trials testing new therapies for MDS and transformed disease are being conducted at medical centers worldwide, including sites in the United States, Europe, and other regions. Patients interested in clinical trial participation should discuss options with their healthcare team. Doctors who specialize in blood disorders can help determine whether any available trials might be appropriate based on a person’s specific disease characteristics, prior treatments, and overall health status.

Eligibility for clinical trials depends on many factors. Most trials have specific requirements regarding prior treatments received, disease stage, genetic abnormalities present, blood counts, organ function, and other health conditions. Some trials specifically enroll patients whose disease has transformed or who have not responded to hypomethylating agents, while others focus on earlier stages of disease. Age restrictions vary—some trials include only younger patients, while others specifically study older individuals who represent the majority of MDS patients.^[6]

Participation in clinical trials offers potential access to promising new treatments before they become widely available. Trial participants also receive extremely close medical monitoring and contribute to medical knowledge that may help future patients. However, clinical trials also involve uncertainties, as experimental treatments may not work or may cause unexpected side effects. Careful discussion with healthcare providers can help individuals make informed decisions about whether trial participation aligns with their goals and circumstances.

Factors Affecting Treatment Response and Survival

Many factors influence how well treatments work and how long people survive after MDS transformation. Understanding these factors helps both patients and doctors set realistic expectations and make informed treatment decisions.

The characteristics of the disease at the time of MDS diagnosis matter significantly. People who started with more advanced disease—higher percentages of blast cells in the bone marrow, more severe blood count abnormalities, or high-risk genetic changes—tend to have worse outcomes after transformation. The type of MDS also influences prognosis. Subtypes called refractory anemia with excess blasts (RAEB-1 and RAEB-2) carry higher transformation risk and poorer outcomes compared to lower-risk subtypes.^[4]

The time it takes for transformation to occur provides prognostic information. Patients whose MDS rapidly progresses to acute leukemia tend to have more aggressive disease and shorter survival compared to those in whom transformation happens more gradually over years. Rapid transformation suggests underlying biology that is particularly resistant to treatment.^[4]

Genetic and chromosomal abnormalities profoundly impact outcomes. Certain chromosomal changes, called cytogenetic abnormalities, are associated with particularly poor prognosis. Complex karyotypes—meaning many different chromosomal abnormalities present simultaneously—indicate aggressive disease unlikely to respond well to treatment. Specific mutations also affect outcomes; as mentioned earlier, TP53 mutations predict especially poor survival after transformation. The total number of mutations present also matters, with higher mutation burdens generally associated with worse outcomes.^[4]

Features present at the time of transformation influence survival as well. Higher white blood cell counts, higher percentages of blasts in the bone marrow, and certain mutation patterns at transformation all correlate with shorter survival times. These factors reflect more aggressive disease biology that tends to overwhelm available treatments.^[4]

Patient characteristics beyond the disease itself also matter. Older age generally predicts worse outcomes, partly because older individuals tolerate intensive treatments less well and partly because disease biology may differ with age. Performance status—how well someone can carry out normal daily activities—significantly affects prognosis. People who are very debilitated or spend most of their time in bed typically cannot undergo aggressive treatments and have shorter survival times. Other medical conditions also limit treatment options and affect outcomes.^[4]

How well someone responds to initial treatment after transformation provides crucial prognostic information. Patients who achieve complete remission—meaning blasts disappear from bone marrow and blood counts normalize—survive longer than those who achieve only partial responses or no response at all. Unfortunately, complete remission rates with available treatments remain disappointingly low for many patients with transformed MDS.

Most Common Treatment Methods

• Supportive Care
  • Red blood cell transfusions to treat anemia and reduce fatigue and shortness of breath
  • Platelet transfusions to prevent bleeding complications when platelet counts are dangerously low
  • Use of leukocyte-depleted blood products to reduce transfusion complications
  • Aggressive management of infections due to low white blood cell counts
  • Growth factors to stimulate bone marrow production in selected cases
• Hypomethylating Agents
  • Azacitidine given by injection under the skin or into a vein in repeated cycles
  • Decitabine administered intravenously following specific dosing schedules
  • Standard of care for higher-risk MDS patients not eligible for transplantation
  • Can slow disease progression and reduce transfusion needs in some patients
  • Eventually stop working in many patients, with limited options after failure
• Immunomodulatory Therapy
  • Lenalidomide particularly effective for patients with deletion 5q genetic abnormality
  • Can eliminate or reduce red blood cell transfusion requirements
  • Given as oral medication in cycles
  • May work in some patients without del(5q), though less consistently
• Intensive Chemotherapy
  • Combination of cytarabine and anthracycline drugs for transformed disease
  • Similar to treatment for acute myeloid leukemia
  • Reserved for younger, healthier patients who can tolerate aggressive treatment
  • Response rates of 30-40 percent, lower than for de novo acute leukemia
  • Requires hospitalization and intensive supportive care
• Stem Cell Transplantation
  • Only potentially curative treatment for myelodysplastic syndromes
  • Involves replacing diseased bone marrow with healthy donor stem cells
  • Limited to younger patients in good health with suitable donors
  • Carries significant risks including graft-versus-host disease and infection
  • Relapse after transplant remains a major concern
• Novel Agents (Clinical Trials)
  • Targeted molecular therapies aimed at specific gene mutations
  • Immunotherapy approaches including checkpoint inhibitors and CAR-T cells
  • Combination regimens with hypomethylating agents plus other drugs
  • New drug classes like telomerase inhibitors (imetelstat)
  • Available at specialized centers conducting clinical trials